{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:10Z","timestamp":1772166430423,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007561","name":"Chiesi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Graft rejection and chronic CNI toxicity remain obstacles to organ transplant success. Current formulations of tacrolimus, such as Prograf\u00ae and Advagraf\u2122, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. As dosing non-compliance can result in graft rejection, the once daily formulation of tacrolimus, Advagraf\u2122, was developed (vs 2x\/day Prograf\u00ae). Benefits of Advagraf\u2122 are counterbalanced by delayed achievement of therapeutic trough levels and need for up to 50% higher doses to maintain Prograf\u00ae-equivalent troughs. Envarsus\u00ae is also a prolonged-release once-daily tacrolimus formulation, developed using MeltDose\u2122 drug-delivery technology to increase drug bioavailability; improved bioavailability results in low patient drug absorption variability and less pronounced peak-to-trough fluctuations. In phase III de novo kidney transplant studies, Envarsus\u00ae proved non-inferior to twice-daily tacrolimus; however, no phase IV studies show superiority of Envarsus\u00ae vs Advagraf\u2122 in de novo liver transplant (LTx) recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The EnGraft compares bioavailability and tests superiority of Envarsus\u00ae (test arm) versus Advagraf\u2122 (comparator arm) in de novo LTx recipients. A total of 268 patients from 15 German transplant centres will be randomised 1:1 within 14\u00a0days post-LTx. The primary endpoint is dose-normalised trough level (C\/D ratio) measured 12\u00a0weeks after randomisation. Secondary endpoints include the number of dose adjustments, time to reach first defined trough level and incidence of graft rejections. Additionally, clinical and laboratory parameters will be assessed over a 3-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>C\/D ratio is an estimate for tacrolimus bioavailability. Improving bioavailability and increasing C\/D ratio using Envarsus could reduce renal dysfunction and other tacrolimus-related toxicities; previous trials have shown that a higher C\/D ratio (i.e. slower tacrolimus metabolism) is not only associated with improved renal function but also linked to reduced neurotoxic side effects. A higher C\/D ratio could improve clinical outcomes for LTx recipients; EnGraft has begun, with one third of patients recruited by January 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial has been registered (4 May 2020) in the EU Clinical Trials Register, EudraCT-Nummer: 2020\u2013000796-20. Additionally, this trial has been registered (22 January 2021) at ClinicalTrials.gov: NCT04720326. The trial received a favourable opinion from the concerned lead ethics committee at the University of Regensburg, under the reference 20\u20131842-112.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07344-7","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T18:01:36Z","timestamp":1683828096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus\u00ae versus Advagraf\u2122 in liver transplant recipients"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-4520","authenticated-orcid":false,"given":"D. S.","family":"W\u00f6hl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brennfleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Holub-Hayles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mutzbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baccar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. K.","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the EnGraft Trial Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian W. R.","family":"Vondran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Herden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Mittler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf Peter","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Nadalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas A.","family":"Schnitzbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Rauchfu\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Willuweit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Croner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"7344_CR1","unstructured":"Guideline on clinical investigation of immunosuppressants for solid organ transplantation. Doc Ref: CHMP\/EWP\/263148\/06. Published 24\/07\/2008. Available from: https:\/\/www.ema.europa.eu\/en\/clinical-investigation-immunosuppressants-solid-organ-transplantation."},{"issue":"18","key":"7344_CR2","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.3748\/wjg.v20.i18.5363","volume":"20","author":"ATW Song","year":"2014","unstructured":"Song ATW, Avelino-Silva VI, Pecora RAA, Pugliese V, D\u2019Albuquerque LAC, Abdala E. Liver transplantation: fifty years of experience. World J Gastroenterol: WJG. 2014;20(18):5363\u201374.","journal-title":"World J Gastroenterol: WJG"},{"issue":"1","key":"7344_CR3","first-page":"1","volume":"7","author":"BV Dasari","year":"2016","unstructured":"Dasari BV, Hodson J, Nassir A, Widmer J, Isaac J, Mergentel H, et al. Variations in practice to therapeutic monitoring of tacrolimus following primary adult liver transplantation. Int J Organ Transplant Med. 2016;7(1):1\u20138.","journal-title":"Int J Organ Transplant Med"},{"issue":"6","key":"7344_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/00007691-199512000-00011","volume":"17","author":"WJ Jusko","year":"1995","unstructured":"Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17(6):606\u201314.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"7344_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139\u201352.","journal-title":"Ther Drug Monit"},{"key":"7344_CR6","unstructured":"Prograf\u00ae SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/prograf."},{"key":"7344_CR7","unstructured":"Advagraf\u00ae SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/advagraf."},{"issue":"6","key":"7344_CR8","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","volume":"67","author":"EM Scholten","year":"2005","unstructured":"Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67(6):2440\u20137.","journal-title":"Kidney Int"},{"issue":"4","key":"7344_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.tp.0000251807.72246.7d","volume":"83","author":"FG Cosio","year":"2007","unstructured":"Cosio FG, Amer H, Grande JP, Larson TS, Stegall MD, Griffin MD. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83(4):411\u20136.","journal-title":"Transplantation"},{"issue":"10","key":"7344_CR10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/j.1600-6143.2010.03255.x","volume":"10","author":"P Trune\u010dka","year":"2010","unstructured":"Trune\u010dka P, Boillot O, Seehofer D, Pinna A, Fischer L, Ericzon BG, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10(10):2313\u201323.","journal-title":"Am J Transplant"},{"key":"7344_CR11","unstructured":"Envarsus\u00ae SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/envarsus."},{"issue":"Suppl 2","key":"7344_CR12","first-page":"185","volume":"26","author":"S Gabardi","year":"2013","unstructured":"Gabardi S, Nigro V, Johnson M, Nachtrieb R, Weinberg J. Evaluation of steady-state pharmacokinetic parameters of LCP-Tacro and Advagraf in healthy volunteers using a systems dynamic model [Abstract P330]. Transpl Int. 2013;26(Suppl 2):185\u2013339.","journal-title":"Transpl Int"},{"issue":"12","key":"7344_CR13","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1111\/ajt.12955","volume":"14","author":"K Budde","year":"2014","unstructured":"Budde K, Bunnapradist S, Griny\u00f3 JM, Ciechanowski K, Denny JE, Silva HT, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial. Am J Transplant. 2014;14(12):2796\u2013806.","journal-title":"Am J Transplant"},{"issue":"3","key":"7344_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/ajt.12035","volume":"13","author":"S Bunnapradist","year":"2013","unstructured":"Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760\u20139.","journal-title":"Am J Transplant"},{"issue":"9","key":"7344_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/ctr.12581","volume":"29","author":"A Langone","year":"2015","unstructured":"Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, et al. Switching STudy of kidney tRansplant pAtients with Tremor to LCP-tacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29(9):796\u2013805.","journal-title":"Clin Transplant"},{"issue":"10","key":"7344_CR16","doi-asserted-by":"publisher","first-page":"e111128","DOI":"10.1371\/journal.pone.0111128","volume":"9","author":"G Th\u00f6lking","year":"2014","unstructured":"Th\u00f6lking G, Fortmann C, Koch R, Gerth HU, Pabst D, Pavenst\u00e4dt H, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS One. 2014;9(10):e111128.","journal-title":"PLoS One"},{"issue":"5","key":"7344_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00228-011-1150-0","volume":"68","author":"P Stratta","year":"2012","unstructured":"Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68(5):671\u201380.","journal-title":"Eur J Clin Pharmacol"},{"key":"7344_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12659\/AOT.895898","volume":"21","author":"G Th\u00f6lking","year":"2016","unstructured":"Th\u00f6lking G, Siats L, Fortmann C, Koch R, H\u00fcsing A, Cicinnati VR, et al. Tacrolimus concentration\/dose ratio is associated with renal function after liver transplantation. Ann Transplant. 2016;21:167\u201379.","journal-title":"Ann Transplant"},{"issue":"2","key":"7344_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ajt.13935","volume":"17","author":"S Tremblay","year":"2017","unstructured":"Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): An open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17(2):432\u201342.","journal-title":"Am J Transplant"},{"issue":"1","key":"7344_CR20","doi-asserted-by":"publisher","first-page":"e13767","DOI":"10.1111\/ctr.13767","volume":"34","author":"A S\u00e1nchez Fructuoso","year":"2020","unstructured":"S\u00e1nchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, Calvi\u00f1o J, et al. Effectiveness and safety of the conversion to MeltDose\u00ae extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study. Clin Transplant. 2020;34(1):e13767.","journal-title":"Clin Transplant"},{"issue":"6","key":"7344_CR21","doi-asserted-by":"publisher","first-page":"E1654","DOI":"10.3390\/jcm9061654","volume":"9","author":"J von Einsiedel","year":"2020","unstructured":"von Einsiedel J, Th\u00f6lking G, Wilms C, Vorona E, Bokemeyer A, Schmidt HH, et al. Conversion from standard-release tacrolimus to MeltDose\u00ae tacrolimus (LCPT) improves renal function after liver transplantation. J Clin Med. 2020;9(6):E1654.","journal-title":"J Clin Med"},{"issue":"9","key":"7344_CR22","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1016\/j.transproceed.2019.03.084","volume":"51","author":"U Baccarani","year":"2019","unstructured":"Baccarani U, Velkoski J, Pravisani R, Adani GL, Lorenzin D, Cherchi V, et al. MeltDose technology vs once-daily prolonged release tacrolimus in de novo liver transplant recipients. Transpl Proc. 2019;51(9):2971\u20133.","journal-title":"Transpl Proc"},{"issue":"4","key":"7344_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/1389200219666180101104159","volume":"19","author":"K Sch\u00fctte-N\u00fctgen","year":"2018","unstructured":"Sch\u00fctte-N\u00fctgen K, Th\u00f6lking G, Suwelack B, Reuter S. Tacrolimus - pharmacokinetic considerations for clinicians. Curr Drug Metab. 2018;19(4):342\u201350.","journal-title":"Curr Drug Metab"},{"issue":"10","key":"7344_CR24","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/jcm8101586","volume":"8","author":"G Th\u00f6lking","year":"2019","unstructured":"Th\u00f6lking G, Sch\u00fctte-N\u00fctgen K, Schmitz J, Rovas A, Dahmen M, Bautz J, et al. A low tacrolimus concentration\/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. J Clin Med. 2019;8(10):1586.","journal-title":"J Clin Med."},{"key":"7344_CR25","doi-asserted-by":"publisher","first-page":"32273","DOI":"10.1038\/srep32273","volume":"6","author":"G Th\u00f6lking","year":"2016","unstructured":"Th\u00f6lking G, Schmidt C, Koch R, Sch\u00fctte-N\u00fctgen K, Pabst D, Wolters H, et al. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016;6:32273.","journal-title":"Sci Rep"},{"issue":"2","key":"7344_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","volume":"9","author":"JM Neuberger","year":"2009","unstructured":"Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the \u201cReSpECT\u201d study. Am J Transplant. 2009;9(2):327\u201336.","journal-title":"Am J Transplant"},{"issue":"11","key":"7344_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","volume":"18","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18(11):2409\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"7344_CR28","doi-asserted-by":"publisher","first-page":"564e575","DOI":"10.1002\/lt.23844","volume":"20","author":"RR Alloway","year":"2014","unstructured":"Alloway RR, Eckhoff DE, Washburn WK, et al. Teperman4 conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl. 2014;20:564e575.","journal-title":"Liver Transpl"},{"issue":"12","key":"7344_CR29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1586\/1744666X.2014.983903","volume":"10","author":"JM Griny\u00f3","year":"2014","unstructured":"Griny\u00f3 JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 2014;10(12):1567\u201379.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"7344_CR30","first-page":"117","volume":"34","author":"C Seger","year":"2010","unstructured":"Seger C, Vogeser M. Immunosuppressant drug monitoring: a routine undertaking? J Lab Med. 2010;34(3):117\u201328.","journal-title":"J Lab Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07344-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T18:02:55Z","timestamp":1683828175000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07344-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7344"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07344-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1662746\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received a favourable opinion from the Ethics Committee of the University of Regensburg, Germany. The vote was given under the reference number 20\u20131842-112. Changes to the trial protocol are only possible via official protocol amendments that are enacted by the trial sponsor. In the event that the protocol is amended, a new signed version of the protocol will be released (with updated version number and date) and circulated to all study staff.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All named authors adhere to the authorship guidelines of Trials. All authors have agreed to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}